DUOX2 and cyclic hematopoiesis: This study indicates that use of current, recommended cutoffs for bsTSH in screening for CH would fail to identify individuals with true dyshormonogenetic CH due to DUOX2 and DUOXA2 mutations, with DUOX2/DUOXA2 cases comprising 50% of the borderline CH cohort.